Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

被引:23
|
作者
Behrouzi, Roya [1 ]
Ryan, Neil A. J. [2 ]
Barr, Chloe E. [3 ]
Derbyshire, Abigail E. [3 ]
Wan, Y. Louise [2 ]
Maskell, Zoe [2 ]
Stocking, Katie [4 ]
Pemberton, Philip W. [5 ]
Bolton, James [6 ]
McVey, Rhona J. [6 ]
Crosbie, Emma J. [2 ,3 ]
机构
[1] Manchester Univ NHS Fdn Trust, Dept Med, Manchester M13 9WL, Lancs, England
[2] Univ Manchester, St Marys Hosp, Fac Biol Med & Hlth, Div Canc Sci, Manchester M13 9WL, Lancs, England
[3] Manchester Univ NHS Fdn Trust, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Obstet & Gynaecol, Manchester M13 9WL, Lancs, England
[4] Univ Manchester, Ctr Biostat, Hlth Serv Res & Primary Care, Div Populat Hlth, Manchester M13 9PL, Lancs, England
[5] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Clin Biochem, Manchester M13 9WL, Lancs, England
[6] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Pathol, Manchester M13 9WL, Lancs, England
关键词
HE4; endometrial cancer; atypical hyperplasia; biomarker; therapy; response; levonorgestrel-releasing intrauterine system; LNG-IUS; PROGNOSTIC MARKER; LONG-TERM; ADENOCARCINOMA; PROGESTIN; THERAPY; WOMEN; METAANALYSIS; MULTICENTER; MANAGEMENT; BIOMARKER;
D O I
10.3390/cancers12020276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 +/- 1.1 pM, 95% confidence interval (CI) 52.7-73.2), compared to non-responders (125.6 +/- 1.3 pM, 95% CI 74.5-211.7, p = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables (p = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders (p = 0.999). Responders showed a significant mean reduction (-9.8 +/- 3.4%, 95% CI -16.7 to -2.8%, p = 0.008) in serum HE4 between baseline and 3 months (p = 0.008), whereas non-responders showed no significant change (p = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months (p > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders (p > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.
引用
收藏
页数:14
相关论文
共 45 条
  • [1] Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study
    Barr, Chloe E.
    Sergeant, Jamie C.
    Agnew, Heather J.
    Bolton, James
    McVey, Rhona J.
    Crosbie, Emma J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2023, 130 (08) : 941 - 948
  • [2] HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
    Orbo, Anne
    Arnes, Marit
    Lysa, Lena Myreng
    Borgfelt, Christer
    Straume, Bjorn
    BRITISH JOURNAL OF CANCER, 2016, 115 (06) : 725 - 730
  • [3] Serum HE4 as a prognostic marker in endometrial cancer - A population based study
    Brennan, Donal. J.
    Hackethal, Andreas
    Metcalf, Alex M.
    Coward, Jermaine
    Ferguson, Kaltin
    Oehler, Martin K.
    Quinn, Michael A.
    Janda, Monika
    Leung, Yee
    Freemantle, Michael
    Webb, Penelope M.
    Spurdle, Amanda B.
    Obermair, Andreas
    GYNECOLOGIC ONCOLOGY, 2014, 132 (01) : 159 - 165
  • [4] Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer
    Hirata, Toru
    Kondo, Eiji
    Magawa, Shoichi
    Kubo-Kaneda, Michiko
    Nii, Masafumi
    Yoshida, Kenta
    Maezawa, Tadashi
    Tabata, Tsutomu
    Ikeda, Tomoaki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (12) : 3219 - 3225
  • [5] HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review
    Karlsen, Nikoline S.
    Karlsen, Mona A.
    Hogdall, Claus K.
    Hogdall, Estrid V. S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (11) : 2285 - 2295
  • [6] HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
    Anne Ørbo
    Marit Arnes
    Lena Myreng Lyså
    Christer Borgfelt
    Bjørn Straume
    British Journal of Cancer, 2016, 115 : 725 - 730
  • [7] Prognostic value of serum HE4 level in the management of endometrial cancer: A pilot study
    Rajadevan, Niveditha
    McNally, Orla
    Neesham, Deborah
    Richards, Anthony
    Naaman, Yael
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2021, 61 (02): : 284 - 289
  • [8] Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer
    Kalogera, Eleftheria
    Scholler, Nathalie
    Powless, Cecelia
    Weaver, Amy
    Drapkin, Ronny
    Li, Jinping
    Jiang, Shi-Wen
    Podratz, Karl
    Urban, Nicole
    Dowdy, Sean C.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (02) : 270 - 275
  • [9] Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer
    Stiekema, A.
    Lok, C. A. R.
    Korse, C. M.
    van Driel, W. J.
    van der Noort, V.
    Kenter, G. G.
    Van de Vijver, K. K.
    VIRCHOWS ARCHIV, 2017, 470 (06) : 655 - 664
  • [10] Combination of serum CST1 and HE4 for early diagnosis of endometrial cancer
    Zhong, Wenhui
    Liu, Yunliang
    Zhang, Liangming
    Zhuang, Wanzhen
    Chen, Jianlin
    Huang, Zhixin
    Zheng, Yue
    Huang, Yi
    PEERJ, 2023, 11